Japanese Cancer Patients Will Have Access to Compensator-Based IMRT with Opening of .decimal, Inc. Office in Tokyo and Hiring of Key... (by Japanese regulatory agencies and look...)

HOME >> MEDICINE >> TECHNOLOGY

Japanese Cancer Patients Will Have Access to Compensator-Based IMRT with Opening of .decimal, Inc. Office in Tokyo and Hiring of Key Personnel

Date:11/4/2009

by Japanese regulatory agencies and looks forward to begin offering their products commercially overseas.

"Cancer centers in Japan will soon have the opportunity to enhance their current radiation delivery capabilities through our unique pay-as-you-go, Internet-based manufacturing business model," said Sweat.

.decimal will be represented in Japan by Sam Tabuchi of Enterprise Florida-Japan. The .decimal office will be located at:

    Sagamiya #2 Building 5F
    10 Ichibancho
    Chiyoda-ku, Tokyo 102-0082
    Phone: 03-3230-0505

.decimal is a medical device manufacturer of patient-specific devices, including missing tissue compensators, modulators for advanced IMRT delivery, as well as apertures and range compensators used in proton therapy. The company has been providing radiation therapy products for over twenty years and serves more than 200 customers. For more information concerning .decimal, please see its Web site at www.dotdecimal.com.

SOURCE .decimal, Inc.

0

GOOD

Page: 1 2
Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
3. Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents
4. Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
5. The Japanese Cancer Association and Debiopharm Group Present the JCA-Mauvernay Award to Dr Ushijima for his Oncology Research
6. BioWa Announces Second Japanese License of POTELLIGENT(R) Technology to Otsuka Pharmaceutical
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
10. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain

Post Your Comments:

Japanese Cancer Patients Will Have Access to Compensator-Based IMRT with Opening of .decimal, Inc. Office in Tokyo and Hiring of Key...(by Japanese regulatory agencies and look...),Health